Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a biopharmaceutical company with a promising outlook due to its lead drug therapy candidate, RenovoGem, currently in a Phase 3 trial to treat Locally Advanced Pancreatic Cancer. The large market potential for this therapy, combined with the positive results from the 1st and 2nd interim analysis, sets the company up for potential success in the future. Additionally, the commercialization of its FDA-cleared medical device, RenovoCath, and the future commercialization of its TAMP therapy platform, indicate strong revenue growth potential.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with a negative outlook due to high risks associated with its product development for pancreatic cancer treatment, low cash and high valuation. Despite the attractive market potential and promising TIGeR-PaC study results, the high risks and uncertainties, such as balance sheet and liquidity risks, failure to gain regulatory approval, and competition, outweigh the potential upside. This is reflected in the low cash reserves and the company's need to raise additional funds through stock sales in the first quarter.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.